Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05715528 · ClinicalTrials.gov registry record · Phase 3
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,011
- Enrollment target
NCT05715528: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT05715528 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 2,011 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05715528, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,011 participants
- Enrollment target
Study Summary
The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
Primary Outcome
The time to alleviation of targeted COVID-19 symptoms by Day 29 for participants with symptom alleviation, was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without symptom alleviation (censored) and without inter-current events, time was calculated as last date/time on which symptom alleviation was assessed minus the first dose date/time or Day 28, whichever occurred first.
Interventions
- DRUG Obeldesivir
- DRUG Obeldesivir Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,011 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 3 |
What the finished NCT05715528 record still lists
NCT05715528 is an interventional study that assigns participants to a tested intervention. Its 2,011 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 2 interventions - of which Obeldesivir is the first listed.
NCT05715528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05715528 about?
NCT05715528 is a clinical study titled "Study of Obeldesivir in Nonhospitalized Participants With COVID-19". The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long...
What is the current status of trial NCT05715528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,011 participants. The study started on 2023-02-08. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT05715528?
The interventions under investigation include: Obeldesivir (DRUG), Obeldesivir Placebo (DRUG).
Who is sponsoring clinical trial NCT05715528?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05715528's enrollment target sits among peer trials
2,011 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI